Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial
Authors:
- 1 October 2019
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 120, 75-85
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK
- Great Ormond Street Hospital Charity
This publication has 22 references indexed in Scilit:
- Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemiaBlood, 2012
- Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemiaBlood, 2011
- Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicityBlood, 2011
- The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answersBritish Journal of Haematology, 2010
- Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2008
- Mechanism-Based Concepts of Size and Maturity in PharmacokineticsAnnual Review of Pharmacology and Toxicology, 2008
- Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trialBritish Journal of Haematology, 2005
- Pharmacokinetics and Pharmacodynamics of Systemically Administered GlucocorticoidsClinical Pharmacokinetics, 2005
- Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?Cancer Treatment Reviews, 2004
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998